HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+17.49%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$1.54B
AUM Growth
+$1.54B
(-7.3%)
Cap. Flow
-$304M
Cap. Flow
% of AUM
-19.78%
Top 10 Holdings %
Top 10 Hldgs %
57.09%
Holding
66
New
11
Increased
18
Reduced
15
Closed
18
Top Buys
| 1 |
McKesson
MCK
|
$68.9M |
| 2 |
MJN
Mead Johnson Nutrition Company
MJN
|
$50.3M |
| 3 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
$36M |
| 4 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
$32.7M |
| 5 |
AGN
ALLERGAN INC
AGN
|
$31.1M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$99.5M |
| 2 |
Zimmer Biomet
ZBH
|
$81.5M |
| 3 |
Intuitive Surgical
ISRG
|
$63M |
| 4 |
AGN
Allergan plc
AGN
|
$58.5M |
| 5 |
AbbVie
ABBV
|
$47M |
Sector Composition
| 1 | Healthcare | 63.75% |
| 2 | Consumer Staples | 9.66% |
| 3 | Financials | 5.14% |
| 4 | Materials | 0.48% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CYNO
26
DELISTED
Cynosure, Inc. Class A
CYNO
| $20M | 1.21% | 750,000 +25,000 | +3% | +$666K |
|
|
27
Intuitive Surgical
ISRG
$170B
| $19.4M | 1.18% | 50,454 -164,100 | -76% | -$63M |
|
28
Exelixis
EXEL
$10.1B
| $19M | 1.15% | 3,100,000 +1,844,650 | +147% | +$11.3M |
|
|
ACGN
29
DELISTED
Aceragen, Inc. Common Stock
ACGN
| $15.5M | 0.94% | 3,350,000 +80,000 | +2% | +$370K |
|
30
Myriad Genetics
MYGN
$593M
| $13.6M | 0.83% | +650,000 | New | +$13.6M |
|
|
31
Gilead Sciences
GILD
$140B
| $13.1M | 0.8% | 175,000 -1,325,000 | -88% | -$99.5M |
|
|
RGLS
32
DELISTED
Regulus Therapeutics
RGLS
| $12.9M | 0.79% | 1,750,000 +775,000 | +79% | +$5.73M |
|
|
ACOR
33
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $11.7M | 0.71% | 400,000 -150,000 | -27% | -$4.38M |
|
34
Biogen
BIIB
$19.4B
| $7.77M | 0.47% | +27,800 | New | +$7.77M |
|
|
MON
35
DELISTED
Monsanto Co
MON
| $7.35M | 0.45% | 63,100 -261,900 | -81% | -$30.5M |
|
36
Teva Pharmaceuticals
TEVA
$21.1B
| $6.62M | 0.4% | +165,200 | New | +$6.62M |
|
|
CLVS
37
DELISTED
Clovis Oncology, Inc.
CLVS
| $5.94M | 0.36% | 98,563 -157,458 | -62% | -$9.49M |
|
38
Merck
MRK
$210B
| $5.71M | 0.35% | +114,100 | New | +$5.71M |
|
39
HCA Healthcare
HCA
$94.5B
| $5.11M | 0.31% | +107,000 | New | +$5.11M |
|
|
40
Zimmer Biomet
ZBH
$21B
| $4.73M | 0.29% | 50,700 -874,300 | -95% | -$81.5M |
|
|
AGN
41
DELISTED
Allergan plc
AGN
| $4.52M | 0.27% | 26,900 -348,100 | -93% | -$58.5M |
|
42
Abbott
ABT
$231B
| $4.5M | 0.27% | +117,300 | New | +$4.5M |
|
43
Thermo Fisher Scientific
TMO
$186B
| $2.95M | 0.18% | 26,500 -14,426 | -35% | -$1.61M |
|
|
CSII
44
DELISTED
Cardiovascular Systems, Inc.
CSII
| $1.72M | 0.1% | +50,000 | New | +$1.72M |
|
|
45
AbbVie
ABBV
$372B
| – | – | -1,050,000 | Closed | -$47M |
|
46
Alkermes
ALKS
$4.78B
| – | – | -825,000 | Closed | -$27.7M |
|
47
Coca-Cola Europacific Partners
CCEP
$40.4B
| – | – | -200,000 | Closed | -$8.04M |
|
48
Celldex Therapeutics
CLDX
$1.47B
| – | – | -26,300 | Closed | -$932K |
|
49
Cooper Companies
COO
$13.4B
| – | – | -21,969 | Closed | -$2.85M |
|
50
CorVel
CRVL
$4.57B
| – | – | -218,000 | Closed | -$8.06M |
|